P04.51. Study of natural health product adverse reactions (SONAR): active surveillance in community pharmacies

  • C Necyk
  • H Boon
  • B Foster
  • W Jaeger
  • D LeGatt
  • G Cembrowski
  • M Murty
  • D Vu
  • R Leitch
  • R Tsuyuki
  • J Barnes
  • T Charrois
  • J Arnason
  • M Ware
  • R Rosychuk
  • S Vohra
Open Access
Poster presentation
  • 831 Downloads

Keywords

Prescription Drug Prescription Medication Active Surveillance Event Data Community Pharmacy 

Purpose

To investigate the adverse event (AE) rates associated with natural health product (NHP) use, prescription drug use and concurrent NHPs-drug use through active surveillance in community pharmacies in Alberta and British Columbia, Canada.

Methods

Participating pharmacists and pharmacy technicians screened consecutive individuals picking up prescription medications about their (1) NHP use, (2) prescription medication use, (3) concurrent NHP/prescription medication use in the previous one month, and (4) the occurrence of potential AEs. If a potential AE was identified and the patient provided written consent, a research pharmacist conducted a guided telephone interview to gather additional detailed information on the AE and medical history of the patient.

Results

Over a total of 105 pharmacy weeks, 1119 patients were screened. Of these patients, 409 reported taking prescription drugs only (36%; 95% CI: 33.7-39.4), 41 reported taking NHPs only (3.7%; 95% CI: 2.6-4.8) and 656 reported taking NHPs and prescription medication concurrently (58.6%; 95% CI: 55.7 to 61.5). A total of 58 patients reported a possible AE, which represents 0.98% (95% CI: 0.03 to 1.93) of those taking prescription medications only, 9.8% of those taking NHPs only (95% CI: 0.7% to 18.9) and 7.5% of those taking NHPs and prescription medications concurrently (95% CI: 5.48 to 9.52).

Conclusion

Compared to passive surveillance, this study found active surveillance to markedly improve NHP adverse event reporting rates. Active surveillance offers improved quantity and quality of adverse event data, allowing for meaningful adjudication to assess potential harms.

Copyright information

© Necyk et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • C Necyk
    • 1
  • H Boon
    • 2
  • B Foster
    • 3
  • W Jaeger
    • 4
  • D LeGatt
    • 5
  • G Cembrowski
    • 5
  • M Murty
    • 6
  • D Vu
    • 6
  • R Leitch
    • 6
  • R Tsuyuki
    • 7
  • J Barnes
    • 8
  • T Charrois
    • 9
  • J Arnason
    • 10
  • M Ware
    • 11
  • R Rosychuk
    • 12
  • S Vohra
    • 1
  1. 1.University of AlbertaEdmontonCanada
  2. 2.Leslie Dan Faculty of PharmacyUniversity of TorontoTorontoCanada
  3. 3.Faculty of MedicineUniversity of OttawaOttawaCanada
  4. 4.Department of MedicineUniversity of AlbertaEdmontonCanada
  5. 5.Department of Laboratory Medicine and PathologyUniversity of AlbertaEdmontonCanada
  6. 6.Health CanadaOttawaCanada
  7. 7.Department of MedicineUniversity of AlbertaEdmontonCanada
  8. 8.School of PharmacyUniversity of AucklandAucklandNew Zealand
  9. 9.School of PharmacyCurtin University of TechnologyPerthAustralia
  10. 10.Department of BiologyUniversity of OttawaOttawaCanada
  11. 11.Research InstituteMcGill University Health CentreMontrealCanada
  12. 12.Department of PediatricsUniversity of AlbertaEdmontonCanada

Personalised recommendations